Committee Leader of North America West Coast Healthcare & Life Sciences Practices. Extensive experience in commercial strategy, long-range planning, M&A assessments and change management with cross-functional teams. Select project experience include:  Healthcare Due Diligence and M&A assessments: Directed five due diligence based on competitive intelligence and strategic recommendations, covering assets from $20M to $2B in revenue medical technology, devices, and healthcare services Biopharma P&L Design & Change Management: Spearheaded the P&L roadmap development for 32 local markets of a $7B biopharma company. Led implementation efforts, incl. training for GMs & functional leads on utilizing P&L for decision-making Pharma Commercialization & Process Simplification: Built a Center of Excellence (CoE) for process simplification, piloted improvements in commercialization processes through LCM touching ~1k FTE for a leading global pharma company Oncology Go-to-Market Strategy: Designed initiatives to rethink brand strategy frameworks and improve patient experience and to grow an oncology product reaching $1B revenue within 1yr post FDA approval Rare Disease Product Strategy: Diagnosed growth challenges for a $1B biotech’s rare disease drug, developed business cases doubling patient penetration and preparing for generic entry by expanding field team and improving medical programming  MedTech GenAI and Innovation: Led evaluation of GenAI use cases for 60K+ FTEs at a $20B medtech company. Defined and aligned leadership on a GenAI ambition and implementation roadmap for productivity & customer experience improvement Pharma Program Management: led a sprint team to develop Scaling Agile Playbook for the roll-out of ~90 new project teams

Calyx is a pioneer in environmental monitoring with patented biology-based gas detection technologies. Applied industry: agriculture, consumer health, cold storage warehousing, commercial building, environmental & safety, etc.Led and advised on GTM strategy, user acquisition & retention, deal negotiation, budget & resource management, and fundraising

Supported Bayer's NUBEQA® (darolutamide) new drug launch. The U.S. Food and Drug Administration (FDA) approved NUBEQA® (darolutamide) for non-metastatic castration-resistant prostate cancer on July 30th, 2019.

• Launched China’s first subscription-based feminine hygiene product eCommerce platform, securing $100K in pre-seed funding• Led product development efforts, analyzed customer insights to build market sizing and pricing models, and worked closely with app developers and suppliers to oversee product roadmaps, supply chain and operations

• Rated “Frequently Exceeding” in all dimensions (Problem Solving, Client Results and Extraordinary Teams); Ranked in top 10% of China/Africa Associate class; Won “Drive Impact” Award (Q3 2016), chosen from ~250 in 3 Greater China offices • Founding member of Nigeria office; served as strategic advisor to then Nigeria’s President on Special Economic Zones initiatives• Strategy consultant specialized in China market entry strategy, R&D strategy, digital platform solutions, Africa-China public-private partnership (PPP), and private equity due diligences / financial modeling